CARLSBAD, Calif.--(BUSINESS WIRE)--Encore Therapeutics Inc. (ETI) today reported results of two pre-clinical efficacy studies demonstrating that its extended release Ropivicaine (ETI-211) can provide anesthetic action for 3 days. ETI-211 is designed for post-surgical pain management; to reduce opiate use and possibly shorten hospital stays.
